J and J wants the strip business and want no competition and Decision Diagnostics countered with J&J advertising that the One Touch system
provides more accurate results than other companies. Genstrip is the name of the testing strips. The article here suggests that J&J could buy them up and get rid of the competition, and I guess court costs versus loss of business will some influence on what happens here.
We used to hear about the J&J stent wars and now we are down to stick wars (glucose strips), but there’s a lot of money in those strips. Before my mother passes away who was a diabetic the mail order pharmacies are all over get those out and even over supplying at times. BD
With more than 250 units making and marketing therapeutic products worldwide, Johnson & Johnson JNJ +0.79% (JNJ) is one of the most diversified global healthcare companies. And as a leader in pharmaceuticals, medical devices, and consumer personal-care products, the company not surprisingly makes sure it adequately protects its turf.
Of late, its largest division, the medical device and diagnostic operations that generates some 40% of the company’s total sales, has been a focus of some of its attention. In particular, it’s defending its product called Lifescan Ultra, used for glucose monitoring in diabetes patients, which is estimated to be a $10 billion market. Right now, J&J dominates the market for single-use strips necessary for patients to use the Lifescan Ultra diagnostic device to check their glucose levels.
J&J, the largest player in this market, filed in September 2011 a patent infringement suit against a small company called Decision Diagnostics and sought an injunction to stop the company from selling its product named Genstrip, an alternative glucose testing strip designed specifically for use with Lifescan Ultra meters.
This time the recall involves Risperdal Consta, the liquid, not the pills so the recalls affect more hospitals and doctor’s offices as not one consumers keep at home. 
health-products maker has issued dozens of recalls for a variety of products, costing it hundreds of millions of dollars sales and prompting close government oversight of some manufacturing plants.
and this is great to see the company working to solve it and look how many years we have in this research and development, 5. It takes time and there’s a lot of robotics and algorithms that go into a project like this. 
I finally put a bunch of it together on one page and 
vast library of unique codes, allowing for improved tracking and authentication of electronics, industrial parts and consumer goods. Each tag’s coded, nano-scale pattern can be scanned using the company’s proprietary instruments. These patterns are like ID numbers that can be associated with a variety of information, such as product strength, site of manufacture, expiration date and country of authorized sale. 
in Newark said this was the most secretive company they had ever worked with so lips have been sealed and due to the nature of the business I can see why. 
mass IT project being totally finished to handle all of it. Now in those states where the Feds are running the show you can expect to see agents at Rite Aid stores. They will be independent and not associated with the store but when a policy is sold, Rite Aid gets a small cut of the sale. There had to be some incentive for Rite Aid in all of this I suppose. 
began in April of this year. SmartD cannot market and pick up new customers as the sanction was in place as CMS said they were a danger to Medicare clients due to some of their current operations methodologies. You can read the CMS letter 
They are not far enough along yet but in one statement in the article is says they are also curious if this could help even “prevent” some cancer development.
he money’s at. Here’s a fairly recent post on how the device folks are flocking to the trade associations and lobbyists of health insurers. 
were going to donate claim information to add to the device and drug files that were being gathered to evaluate for safety along with medical records added? Dr. Hamburg has talked about the program quite favorably as it is helping with safety devices and drugs, but did the insurance companies decide not to send claim information to the FDA and decide to make a buck instead selling data? About the FDA Sentinel below:
a focus on improving health care quality and outcomes, according to a news release. The partnership aims to address the challenges of improving quality of care and reducing treatment costs.
to fight HIV-1 infections. 
on the drugs in production at Onyx and this must have done the trick for Amgen to give the go ahead to buy. Last year Onyx made the news with their approval of a new skin cancer drug. The drug comes under the category of one of the life extending drugs on the market. 
to do a large number of tests at one time and there’s the remote connectivity so all don’t have to physically be in one place. The videos below explain a bit more on how the system works and I would venture to say that the product stands to save some man hours with getting large numbers of results done at once. 4 target slides can be loaded at once with multi stations for collaboration for 4 technologists to work at the same time. There’s middle ware software that does the connecting.
sale and the ability to query additional data bases. I have said many times that Walgreens makes about a billion a year on selling data only and of course one would guess that CVS is right up there with them. They all do it. I said a while back that we needed to take HIPAA out of the HHS silo and republish the provisions in other areas to easy access for consumers is there. We have a lot of new entities now that fall under the provisions of HIPAA, so this makes perfect sense.
Now don’t think they are totally good guys here with dropping this entirely, it’s probably just that they found a cheaper way to get data and analyze it. 
It is using a web portal and requires a USB connection to your computer. Controlling diabetes and hypertension are the main chronic conditions targeted with the system and the targeted sales for the service/devices are insurance companies and home healthcare agencies. 
company acquired for analyzing mood disorders and depression and I am guessing this applies here as the company is also working on mood and depression measurement systems whereby the patent is specific. 
with a user's interface to record heart sounds and 3 Lead ECG signals for analysis in real time. The cloud maintains an extensive library of cardiac murmurs (including congenital heart disease) and heart sounds database. The sounds have been recorded from real patients at the four main auscultation locations (aortic, pulmonary, tricuspid and mitral) with the diagnosis confirmed by means of echocardiography. The computer logarithms with a 90% or more accuracy assist in the diagnoses of pathological and physiological heart murmurs even at heart rates of up to 180 bpm!”
changes, so does how regulation takes place. Again, if the ONC had specific questions or needed certain tests the FDA resources would be there. Also if the FDA would have the expertise of consulting the ONC as well. The ONC could be it’s own division and I think the collaboration between the FDA and ONC would probably be very good. 
was no non hormonal drug out there for hot flashes? It supposedly met the goals in clinical trials but those who voted against it said it was only minimally effective. Does it do better than natural black cohosh is the question that comes to mind. So I guess if one is on Paxil that has the same active ingredient, you could be getting a double bang for the buck? We do know that hormones work but they also have their inherent cancer dangers as well. If you want to learn more about hot flashes scroll down and check out